Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model

Cytokine

Volumn 65, Issue 2, 2014, Pages 236-244

  Harvey, B S ^a   Sia, T C ^b   Wattchow, D A ^b   Smid, S D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Anandamide; Cannabidiol; Colitis; Epithelial permeability; Interleukin 17

Indexed keywords

ANANDAMIDE; CANNABIDIOL; INTERLEUKIN 17; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CLINICAL ARTICLE; COLITIS; COLON INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CRYPT; LAMINA PROPRIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANANDAMIDE; CANNABIDIOL; COLITIS; EPITHELIAL PERMEABILITY; INTERLEUKIN 17;

ARACHIDONIC ACIDS; BLOTTING, WESTERN; CACO-2 CELLS; CANNABIDIOL; CELL MEMBRANE PERMEABILITY; ELECTRIC IMPEDANCE; ENDOCANNABINOIDS; EPITHELIAL CELLS; EPITHELIUM; HUMANS; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LIGANDS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; POLYUNSATURATED ALKAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892484466     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.10.006     Document Type: Article

References (55)

1. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease (report). Nature 2007, 448. 427(8).
2. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol 2011, 142:46-54.
3. Wilson J., Hair C., Knight R., Catto-Smith A., Bell S., Kamm M., et al. High incidence of inflammatory bowel disease in Australia: A prospective population-based Australian incidence study. Inflamm Bowel Dis 2010, 16:1550-1556.
4. Hering N.A., Fromm M., Schulzke J.D. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012, 590:1035-1044.
5. Clayburgh D.R., Barrett T.A., Tang Y., Meddings J.B., Van Eldik L.J., Watterson D.M., et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 2005, 115:2702-2715.
6. Mankertz J., Schulzke J.D. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007, 23:379-383.
7. Schreiber S., Nikolaus S., Hampe J., Hamling J., Koop I., Groessner B., et al. Tumour necrosis factor a and interleukin 1-b in relapse of Crohn's disease. Lancet 1999, 353:459-461.
8. Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., et al. TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. Am J Physiol - Gastrointest Liver Physiol 2004, 286:G367-G376.
9. Al-Sadi R., Ye D., Said H.M., Ma T.Y. Cellular and molecular mechanism of interleukin-1b; modulation of CACO-2 intestinal epithelial tight junction barrier. J Cell Mol Med 2010, 15:970-982.
10. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003, 171:6164-6172.
11. Nicotra L.L., Vu M., Harvey B.S., Smid S.D. Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins Other Lipid Mediat 2013, 100-101:22-29.
12. Jarry A., Bossard C., Bou-Hanna C., Masson D., Espaze E., Denis M.G., et al. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J Clin Invest 2008, 118:1132-1142.
13. Harvey B.S., Smid S.D. The gastrointestinal endocannabinoid system in health and inflammation. Curr Top Pharmacol 2012, 16:107-118.
14. Guglani L., Khader S.A. Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS 2010, 5:120-127.
15. O'Connor W., Zenewicz L.A., Flavell R.A. The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol 2010, 11:471-476.
16. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489.
17. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
18. Rovedatti L., Kudo T., Biancheri P., Sarra M., Knowles C.H., Rampton D.S., et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009, 58:1629-1636.
19. Lee J.W., Wang P., Kattah M.G., Youssef S., Steinman L., DeFea K., et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008, 181:6536-6545.
20. Sheibanie A.F., Yen J.H., Khayrullina T., Emig F., Zhang M., Tuma R., et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J Immunol 2007, 178:8138-8147.
21. Liu Z., Jiu J., Liu S., Fa X., Li F., Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007, 29:187-194.
22. Lee W.W., Kang S.W., Choi J., Lee S.H., Shah K., Eynon E.E., et al. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010, 115:530-540.
23. Curtis M.M., Way S.S. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009, 126:177-185.
24. Abraham C., Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1090-1100.
25. Kinugasa T., Sakaguchi T., Gu X., Reinecker H.C. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 2000, 118:1001-1011.
26. Pappu R., Rutz S., Ouyang W. Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol 2012, 33:343-349.
27. Reynolds J.M., Martinez G.J., Nallaparaju K.C., Chang S.H., Wang Y.H., Dong C. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol 2012, 189:4226-4230.
28. Yapici Ü., Roelofs J.J.T.H., Florquin S. The importance of testing anti-IL-17 antibodies from different suppliers. Am J Transplant 2012, 12:504-505.
29. Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J., et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J immunol 2008, 181:2799-2805.
30. Wedebye Schmidt E.G., Larsen H.L., Kristensen N.N., Poulsen S.S., Lynge Pedersen A.M., Claesson M.H., et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis 2013, 19:1567-1576.
31. Borrelli F., Aviello G., Romano B., Orlando P., Capasso R., Maiello F., et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009, 87:1111-1121.
32. Massa F., Marsicano G., Hermana H., Cannich A., Monory K., Cravatt B.F., et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004, 113:1202-1209.
33. Cencioni M.T., Chiurchiu V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 2010, 5:e8688.
34. Schicho R., Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012, 89:149-155.
35. De Filippis D., Esposito G., Cirillo C., Cipriano M., De Winter B.Y., Scuderi C., et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE 2011, 6:e28159.
36. Meijer M.J., Mieremet-Ooms M.A., van Duijn W., van der Zon A.M., Hanemaaijer R., Verheijen J.H., et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:200-210.
37. Ramirez-Carrozzi V., Sambandam A., Luis E., Lin Z., Jeet S., Lesch J., et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011, 12:1159-1166.
38. Harvey B.S., Nicotra L.L., Vu M., Smid S.D. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine 2013, 63:209-217.
39. Kruschewski M., Foitzik T., Perez-Canto A., Hubotter A., Buhr H.J. Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system. Dig Dis Sci 2001, 46:2336-2343.
40. Kimball E.S., Schneider C.R., Wallace N.H., Hornby P.J. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006, 291:G364-G371.
41. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
42. Newton R. Molecular mechanisms of glucocorticoid action: what is important?. Thorax 2000, 55:603-613.
43. Macdonald D.C., Leir S.H., Brooks C., Sanders E., Lackie P., Rosenberg W. CD44 isoform expression on colonic epithelium mediates lamina propria lymphocyte adhesion and is controlled by Th1 and Th2 cytokines. Eur J Gastroenterol Hepatol 2003, 15:1101-1110.
44. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
45. Takahashi N., Vanlaere I., de Rycke R., Cauwels A., Joosten L.A.B., Lubberts E., et al. IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med 2008, 205:1755-1761.
46. D'Argenio G., Valenti M., Scaglione G., Cosenza V., Sorrentini I., Di Marzo V.D. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006, 20:568-570.
47. Smid S.D. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine. Clin Exp Pharmacol Physiol 2008, 35:1383-1387.
48. Esposito G., Filippis D.D., Cirillo C., Iuvone T., Capoccia E., Scuderi C., et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res: PTR. 2012, 27:633-636.
49. Mäkitalo L., Rintamäki H., Tervahartiala T., Sorsa T., Kolho K.-L. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 2012, 47:785-794.
50. Han Y.P., Tuan T.L., Wu H., Hughes M., Garner W.L. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 2001, 114:131-139.
51. Lionetti P., Breese E., Braegger C.P., Murch S.H., Taylor J., MacDonald T.T. T-cell activation can induce either mucosal destruction or adaptation in cultured human fetal small intestine. Gastroenterology 1993, 105:373-381.
52. Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997, 158:1582-1590.
53. Madara J.L., Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989, 83:724-727.
54. Lahdenpera A.I., Holtta V., Ruohtula T., Salo H.M., Orivuori L., Westerholm-Ormio M., et al. Up-regulation of small intestinal interleukin-17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes. Clin Exp Immunol 2012, 167:226-234.
55. Chow W.L., Lee Y.K. Free fucose is a danger signal to human intestinal epithelial cells. Br J Nutr 2008, 99:449-454.